These include TNF-alpha inhibitors during the acute stage or for cases of corneal melt secondary to ocular SJS/TEN, a combination of anti-VEGF and PDT therapy for patients with refractory corneal neovascularization, lacrimal system irrigation using corticosteroids for patients with epiphora and lacrimal duct obstruction, and lastly, 5-fluorouracil as an anti-fibrotic agent for conjunctival scarring and chronic dry eye [127,128,144,147,157,175,188,201,202]. The gene discussed is VEGFA; the disease is Epiphora.